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Abstract
Background: Neuroendocrine neoplasms (NENs) comprise a wide-ranging group of abnormal neoplasms with atypical
presentations, from primary localized disease to extensive metastasis, reaching the bone and brain. The NENs are
divided into two major groups: neuroendocrine tumors (NETs), which are well-differentiated tumors of any grade, and
neuroendocrine carcinomas (NECs), which are poorly differentiated, high-grade cancers with a high risk of morbidity
and mortality. The challenge of diagnosing NENs early, particularly prior to metastasis, highlights the importance of
further studying these diseases. We present a case of aggressive metastatic neuroendocrine carcinoma of a gastrointestinal/pancreaticobiliary origin.
Case summary: A 54-year-old male with a past medical history of hypertension and left total hip replacement presented
with generalized weakness, dyspnea on exertion, decreased appetite, and fatigue for one month. Initial laboratory
ﬁndings noted a hemoglobin level of 3.1 g/dL and a platelet count of 9 £ 109/L. CT scan ﬁndings revealed a splenic
infarct, lytic bone lesions, and small bilateral occipital hemorrhages. Bone marrow biopsy was consistent with metastatic, high-grade, poorly differentiated neuroendocrine carcinoma favoring a gastrointestinal/pancreaticobiliary origin.
The patient expired shortly after starting chemotherapy due to the extensive disease.
Conclusion: Neuroendocrine neoplasms may be discovered late in their course with distant metastatic spread and thus
have a poor prognosis. This case report and literature review describes the presentation of metastatic high-grade
neuroendocrine carcinoma in a patient presenting to a community hospital, and reviews the current literature and
guidelines on neuroendocrine carcinomas.
Keywords: Neuroendocrine neoplasms (NEN), Neuroendocrine tumors (NETs), Neuroendocrine carcinoma (NEC),
Gastroenteropancreatic neuroendocrine tumor (GEP-NET), Case report

1. Introduction

N

euroendocrine neoplasms (NENs) are uncommon neoplasms that arise from widely
dispersed specialized cells. The term “neuroendocrine” is based on two aspects of these cells: their
secretory dense core granules (DCGs), similar to
those in serotonergic neurons and their ability to
synthesize and secrete these granules. The neuroendocrine (NE) system involves endocrine glands,
mostly the pituitary, parathyroid, thyroid, adrenal
medulla, and dispersed among the gastrointestinal
and respiratory tracts.1 The most recent iteration of

the WHO classiﬁcation for digestive system tumors
divides NENs into neuroendocrine tumors (NET:
well-differentiated, any grade) and neuroendocrine
carcinomas (NECs: poorly differentiated, highgrade by deﬁnition) based on their molecular differences.2,3 Historically, well-differentiated NENs
are referred to as carcinoid tumors, and poorly
differentiated high-grade neuroendocrine carcinomas are classiﬁed similarly to small cell lung
carcinomas. The gastrointestinal tract and lungs are
the most common primary tumor sites.1 Metastases
occur to the brain, lymph nodes, liver and bones.4
Standard of care treatment involves surgery and/or
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cytotoxic chemotherapy regimens, and treatment
guidelines are constantly evolving. We review a case
of a patient presenting for symptomatic anemia,
with bone marrow biopsy supporting the diagnosis
of metastatic high-grade neuroendocrine carcinoma
of a gastrointestinal origin, and present the current
literature and guidelines on this disease.

2. Case report
A 54-year-old African American male with a past
medical history of hypertension and left total hip
arthroplasty presented to the emergency department complaining of chest pain, decreased appetite,
weight loss, and fatigue. He reported one melanotic
bowel movement approximately three weeks prior.
He denied diarrhea, headache, shortness of breath,
palpitations, ﬂushing, nausea, vomiting, abdominal
pain, hematemesis, dysuria, hematuria, skin lesions,
or other symptoms. Physical examination revealed a
heart rate of 101 bpm and respiratory rate of 25
breaths per minute. The patient was alert and oriented with no neurological deﬁcits and did not
appear cachectic. The remainder of the examination
revealed scleral icterus and no heart murmurs or
wheezing. Bowel sounds were normoactive, no
abdominal tenderness was elicited, and no palpable
mass or organomegaly was appreciated. Digital
rectal examination revealed no hemorrhoids,
masses, or frank blood. Petechiae were visible on
the skin, without ecchymosis or bruising, and extremities were thin and without edema; fecal occult
blood was positive.
Initial laboratory studies revealed hemoglobin
3.1 g/dL, platelets 9  109/L, creatinine 1.5 mg/dL,
AST 124 U/L, and ALT 37 U/L. Other laboratory
ﬁndings included reticulocyte count 6.54%, total
calcium 10.1 mmol, D-dimer >4.3 mcg/mL, ﬁbrinogen 234.2 mg/dL, uric acid 10.4 mg/dL, CEA
62.6 ng/mL, PTH 13.9 pg/mL and LDH 2417 U/L.
Examination of the peripheral smear revealed
circulating blasts, leading to suspicion for acute
myeloid leukemia (AML). An initial CT of the chest,
abdomen, and pelvis without contrast showed
diffuse interstitial markings with dependent atelectasis at the lung bases, small bilateral pleural
effusions, and small right diaphragmatic lymph
nodes. The liver demonstrated no focal lesions;
there was mild hepatic enlargement, but contours
were maintained. The spleen was noted to have a
3.5 cm ill-deﬁned hypodensity. Per the radiologist's
review, differentials included an infarct, hemangioma, or metastatic disease. A previously noted
fracture in the left iliac crest was unchanged, concerning for a lytic lesion. A review of previous CT

ﬁndings from approximately three weeks prior
(when the patient presented for left leg pain)
revealed the known left total hip arthroplasty with
streak artifact in the pelvis, a fracture of the anterior aspect of the left iliac crest, and a possible
associated lytic lesion, which had not been noted
on left hip x-ray from that same day. Further
evaluation included a CT brain without contrast
which revealed small bilateral occipital hemorrhages (approximately 1.5 cm), a left basal ganglia
hemorrhage, a questionable small infarct in the
right frontal cortex, as well as concern for hemorrhagic metastases; there was no ﬂuid collection,
mass effect, or shift.
The patient was admitted to the intensive care
unit for acute severe anemia with concern for acute
myeloblastic crisis. He received pantoprazole,
octreotide, and packed red blood cells. A bone
marrow biopsy was scheduled but was delayed due
to thrombocytopenia and the patient's critical condition. Oncology recommended transferring the
patient to a tertiary cancer center to initiate treatment; however, the patient was too unstable. He
was started on allopurinol for elevated uric acid to
protect against tumor lysis syndrome. Although the
CT ﬁndings warranted further evaluation via MRI,
the patient had had a metal pellet in his head which
prohibited MRI studies. A repeat CT chest,
abdomen, and pelvis revealed multiple lytic lesions
in the left clavicle, with possible fracture, as well as
in the sacrum and ilium (Fig. 1). The bone marrow
biopsy was completed on the fourth day of hospitalization. The immunohistochemistry (Fig. 2 and
Table 2) was positive for synaptophysin, pancytokeratin, patchy chromogranin, CDX2, and villin,
the combination of which supported the diagnosis
of metastatic, high-grade, poorly differentiated
neuroendocrine carcinoma (NEC) favoring a
gastrointestinal pancreaticobiliary origin, invading
the majority of the bone marrow.
On the tenth day of hospitalization, the patient
started the ﬁrst course of chemotherapy with
reduced dose carboplatin and etoposide, along with
rasburicase for prevention of tumor lysis syndrome,
and dexamethasone. He received three days of
carboplatin and etoposide. The patient continued to
have hemoglobin levels in the 7e9 g/dL range
during the hospitalization and required numerous
blood and platelet transfusions; the persistently low
hemoglobin was attributed to bone marrow inﬁltration and bleeding due to thrombocytopenia. His
clinical condition deteriorated during the hospitalization; four weeks after admission the patient
required mechanical ventilation as well as emergent
hemodialysis for worsening renal function. He
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Fig. 1. Computed tomography of the chest, abdomen, and pelvis.

subsequently expired on the thirty-eighth hospital
day.

3. Discussion
NENs encompass approximately 0.5% of all newly
diagnosed malignancies, and account for less than
200,000 cases in the United States. The incidence of
NENs has been growing consistently, likely due to
improved recognition of the disease.1,5 The most
common primary sites for NENs are the gastrointestinal tract and lungs, with approximately 62%e
67% and 22%e27% of cases, respectively. Within the
GI tract, these neoplasms can be found in the small
intestine, rectum, colon, pancreas, and appendix.
Females are more prone to NENs of the stomach,
appendix, or cecum, while males are more likely to
be diagnosed with NENS of the jejunum/ileum,
duodenum, and rectum.5 Metastatic disease rates
range from 12% to 73%, with some studies showing
40%e50% of patients with NENs found with distant
metastases on diagnosis.1,4 NENs often appear
sporadically, but there is an association with multiple endocrine neoplasia type 1 syndrome (MEN1),
and familial clustering has been detected. Although
alcohol and tobacco use are risk factors for a
multitude of neoplasms, there does not seem to an
association in NENs. In this report we focus on
NENs of a gastroenteropancreatic origin.
Due to the variability in presentations and other
factors associated with NENs, it has been notoriously difﬁcult to classify them taxonomically. The
2019 WHO classiﬁcation criteria of NETs incorporate differentiation, grade, mitotic rate, and the Ki67 index (Table 1). The grading system recognizes
two classes: well- and poorly-differentiated neoplasms, or NETs and NECs, respectively. NETs are
further classiﬁed into G1, G2 and G3; NECs are
poorly differentiated and high grade by deﬁnition,

they are no longer graded, but rather classiﬁed into
large and small cell types.2
Immunohistochemistry is an important tool in the
diagnosis of cancers, with biopsy and staining being
the gold standard. Well-differentiated NET cells can
be recognized by large quantities of secretory
granules with intense immunoexpression of
neuroendocrine markers such as chromogranin A
(CgA) and synaptophysin (Syn); in contrast, NECs
can be identiﬁed by the solid “sheet-like” proliferation of cells with irregular nuclei, fewer cytoplasmic granules, and many mitotic features, as
seen on the bone marrow biopsy obtained from the
patient presented in this case. Immunohistochemical staining of NECs will, contrary to the NETS,
reveal a diffuse expression of Syn and indistinct
staining of CgA.1 The bone marrow biopsy shows
the intense, compact, immature cells seen under the
H&E stain in 100x and 400x in box A and B,
respectively of Fig. 2. Box C reveals positive staining
for chromogranin, a sensitive marker for neuroendocrine tumors. Box D indicates the positive staining for synaptophysin, which as mentioned, is
associated with secretory granules typical of
neuroendocrine cells. Furthermore, staining for
CDX2, as seen in Box E, is positive, supporting a GI
source of the neoplasm. The staining in Box F represents pancytokeratin staining, which provides
further evidence of a neuroendocrine origin for
these cells found in the bone marrow. Finally, Box G
exempliﬁes the high mitotic index and high cellular
proliferation indicated by staining for Ki-67, which
in this patient was evaluated to be upwards of 90%,
indicating a highly mitotically active and likely
aggressive tumor.1
The pathogenesis and clinical manifestation of the
NENs are associated with the functionality of the
tumor, as well as any pathology that occurs due to
growth or metastasis of the disease, such as
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Fig. 2. Immunohistochemistry of bone marrow aspirate.

increased vasculature or impingement of neurovascular structures.6 While less than half (40%) of
NETs are hormone producing, clinical signs and
symptoms may be attributed to the type of hormones that are produced by the tumors. Thus, patients with gastroenteropancreatic tumors may
present with abdominal pain, nausea, vomiting,
weight loss and early satiety. Classic symptoms of
carcinoid tumor will reveal physical examination
ﬁndings of ﬂushed skin, tachycardia, heart murmur
or wheezing. Other speciﬁc hormone producing
NENs such as insulinomas, gastrinomas, glucagonomas, VIPomas, and somatostatinomas produce
their respective hormone and related symptoms.

Additionally, there is activation of proangiogenic
factors and ﬁbroblasts, leading to the vascularity
and metastatic qualities of NETs. NECs on the other
hand are so poorly differentiated that they are unlikely to cause hormone-related symptoms. In the
setting of bone marrow metastasis, as in the patient
in the vignette, anemia and bleeding may be presenting signs.
Similar to the clinical signs and symptoms, laboratory evaluation of blood counts and electrolytes
will often coincide with the functionality of the
offending tumor. Other laboratory ﬁndings include
elevated urinary 5-hydroxyindole acetic acid (5HIAA) levels, supporting carcinoid syndrome. In the

Table 1. Adapted from the WHO 2019 guidelines on grading of NENs. NET, Neuroendocrine tumor; NEC, Neuroendocrine carcinoma; SCNEC,
Small-cell neuroendocrine carcinoma; LCNEC, Large-cell neuroendocrine carcinoma.
Terminology

Differentiation

Grade

Mitotic rate

Ki-67 index

NET, G1
NET, G2
NET, G3
NEC, small-cell type (SCNEC)
NEC, large-cell type (LCNEC)

Well differentiated

Low
Intermediate
High
High

<2
2e20
>20
>20
>20

<3%
3e20%
>20%
>20%
>20%

Poorly differentiated

Table 2. Summary of immunohistochemical ﬁndings.
Immunohistochemistry markers

Results

Pancytokeratin
CD56
Synaptophysin
Chromogranin
Thyroid transcription factor-1
Ki-67
CDX-2
Villin

Positive
Negative
Positive
Patchy positivity
Negative
90%
Positive
Positive

case of metastatic disease to the liver, an elevation in
liver function tests may be observed. As found in
our patient presenting to our community hospital,
symptomatic anemia may have been due to blood
loss via GI tract, hemolysis, as evidenced by the
elevated LDH, or poor production, whether of red
blood cells or platelets, which would be a plausible
explanation given the bone marrow metastases.7
Bone marrow inﬁltration may result in pancytopenia as well as hypercalcemia, as evidenced in our
patient. Of note, it has been suggested that hypercalcemia is a rare ﬁnding in bone metastases secondary to NETs, with only 4% of cases being
reported; hypercalcemia is more commonly associated with pheochromocytomas or sympathetic paragangliomas,
compared
to
gastropancreatic
carcinomas.8 Another study revealed that 44e73% of
patients with NETs present with metastatic disease,
and bone involvement is likely underestimated and
oftentimes found post-mortem.9
Treatment of NETs involves surgery and/or
cytotoxic chemotherapy regimens. Patients may
beneﬁt from radiotherapy. Poorly differentiated
NECs require multimodal approaches similar to
small cell lung cancer management. Surgical
resection is highly suggested for localized tumors.
Somatostatin analogues such as octreotide and
lanreotide affect somatostatin receptors and have
been shown to decrease the tumor growth with
antisecretory and antitumor growth efﬁcacy; however, these are mostly for symptom control and do
not affect outcomes.5,9,10 Everolimus or peptide receptor radionuclide therapy (PRRT) with lutetium177 dotatate (177 Lu-DOTATATE) has been
approved for advanced GEP-NETs. Everolimus is
effective on a wide spectrum of NENs, and the
antiangiogenic agent sunitinib has been approved
for pancreatic NENs. Multiple retrospective studies
have reported the efﬁcacy of liver-directed therapies both for palliating symptoms of hormone
excess and for controlling tumor growth. Our patient received dose adjusted carboplatin and etoposide, options for patients with unresectable and
metastatic disease.5,9
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Our patient received allopurinol due to the
elevated uric acid level and the concern for tumor
lysis syndrome. When chemotherapy was initiated,
a single 7.5 mg infusion of rasburicase was administered. Rasburicase was added because he was
considered at high risk for tumor lysis syndrome
due to the high-grade neuroendocrine carcinoma.
The FDA recommends that high-risk patients (such
as patients of African descent) be screened for
glucose-6-phosphate dehydrogenase (G6PD) deﬁciency prior to starting rasburicase as the medication is known to cause hemolytic anemia in highrisk populations; however, our patient was not
screened.11 As mentioned earlier, his consistently
low hemoglobin levels during the hospitalization
were attributed to bone marrow inﬁltration and
bleeding due to thrombocytopenia.

4. Conclusion
Neuroendocrine neoplasms have the potential to
quickly metastasize therefore a timely diagnosis is
imperative to survival. Clinicians should suspect
this malignancy in patients presenting with anemia
or pancytopenia.

Funding
None.
Conﬂict of interest
No relationships with industry. No conﬂicts of
interest.

Acknowledgements
Department and institution where work was done:
Critical Care Department/Long Island Community
Hospital, 101 Hospital Road, Patchogue, New York
11772

References
1. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but
NET: a review of neuroendocrine tumors and carcinomas.
Neoplasia.
2017;19(12):991e1002.
https://doi.org/10.1016/
j.neo.2017.09.002.
2. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M,
Schirmacher P, Washington KM, Carneiro F, Cree IA, WHO
Classiﬁcation of Tumours Editorial Board. The 2019 WHO
classiﬁcation of tumours of the digestive system. Histopathology. 2020;76(2):182e188. https://doi.org/10.1111/his.13975.
3. Gonzalez RS. Diagnosis and management of gastrointestinal
neuroendocrine neoplasms. Surg Pathol Clin. 2020;13(3):
377e397.
4. Pavel M, O'Toole D, Costa F, Capdevila J, Gross D,
Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF,
€
Oberg
K, Vienna Consensus Conference participants. ENETS
consensus guidelines update for the management of distant

CASE REPORT

JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES 2022;12:83e88

88

JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES 2022;12:83e88

CASE REPORT

metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary
site. Neuroendocrinology. 2016;103(2):172e185. https://doi.org/
10.1159/000443167.
5. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA A Cancer J Clin. 2018;68(6):471e487. https://
doi.org/10.3322/caac.21493.
6. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K,
Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah M,
Bergsland EK. Bone metastases and skeletal-related events
from neuroendocrine tumors. Endocr Connect. 2015;4(1):
9e17.
7. Ahmed M. Gastrointestinal neuroendocrine tumors in 2020.
World J Gastrointest Oncol. 2020;12(8):791.

8. Zamborsky R, Svec A, Kokavec M, Galbavy S. Bone metastases in neuroendocrine tumors. Bratisl Lek Listy. 2017;118(9):
529e534.
9. Scharf M, Petry V, Daniel H, Rinke A, Gress TM. Bone metastases in patients with neuroendocrine neoplasm: frequency
and clinical, therapeutic, and prognostic relevance. Neuroendocrinology. 2018;106(1):30e37.
10. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E,
Berlin JD, Halperin D, Zuccarino-Catania G. NCCN guidelines insights: neuroendocrine and adrenal tumors, version
2.2018. J Natl Compr Cancer Netw. 2018;16(6):693e702.
11. Sanoﬁ. Elitek (rasburicase) highlights of prescribing information;
2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/
2009/103946s5083lbl.pdf.

